These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24231947)

  • 1. Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy.
    Necchi A; Pennati M; Zaffaroni N; Landoni E; Giannatempo P; Raggi D; Schwartz LH; Morosi C; Crippa F; Farè E; Nicolai N; Lanocita R; Sava T; Sacco C; Messina C; Ortega C; De Braud FG; Salvioni R; Daidone MG; Gianni AM; Mariani L
    Br J Cancer; 2014 Jan; 110(1):26-33. PubMed ID: 24231947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
    Nikolinakos PG; Altorki N; Yankelevitz D; Tran HT; Yan S; Rajagopalan D; Bordogna W; Ottesen LH; Heymach JV
    Cancer Res; 2010 Mar; 70(6):2171-9. PubMed ID: 20215520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
    Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
    Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
    Necchi A; Mariani L; Zaffaroni N; Schwartz LH; Giannatempo P; Crippa F; Morosi C; Lanocita R; Sava T; Ortega C; Messina C; Sacco C; Pennati M; Daidone MG; Nicolai N; De Braud F; Gianni AM; Salvioni R
    Lancet Oncol; 2012 Aug; 13(8):810-6. PubMed ID: 22819172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma.
    Maiorano BA; Schinzari G; Carbone C; Piro G; Rossi E; Di Maio M; Di Giacomo A; Maiello E
    Front Immunol; 2024; 15():1401214. PubMed ID: 38799450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.
    Zurita AJ; Gagnon RC; Liu Y; Tran HT; Figlin RA; Hutson TE; D'Amelio AM; Sternberg CN; Pandite LN; Heymach JV
    Br J Cancer; 2017 Aug; 117(4):478-484. PubMed ID: 28683470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).
    Grande E; Capdevila J; Castellano D; Teulé A; Durán I; Fuster J; Sevilla I; Escudero P; Sastre J; García-Donas J; Casanovas O; Earl J; Ortega L; Apellaniz-Ruiz M; Rodriguez-Antona C; Alonso-Gordoa T; Díez JJ; Carrato A; García-Carbonero R
    Ann Oncol; 2015 Sep; 26(9):1987-1993. PubMed ID: 26063633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.
    Bellmunt J; González-Larriba JL; Prior C; Maroto P; Carles J; Castellano D; Mellado B; Gallardo E; Perez-Gracia JL; Aguilar G; Villanueva X; Albanell J; Calvo A
    Ann Oncol; 2011 Dec; 22(12):2646-2653. PubMed ID: 21427062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel.
    Korantzis I; Kalogeras KT; Papaxoinis G; Kotoula V; Koutras A; Soupos N; Papakostas P; Dionysopoulos D; Samantas E; Christodoulou C; Linardou H; Pectasides D; Fountzilas G
    Anticancer Res; 2012 Oct; 32(10):4569-80. PubMed ID: 23060588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.
    Narayanan S; Lam A; Vaishampayan U; Harshman L; Fan A; Pachynski R; Poushnejad S; Haas D; Li S; Srinivas S
    Clin Genitourin Cancer; 2016 Oct; 14(5):432-437. PubMed ID: 27068017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
    Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
    Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma.
    Pinciroli P; Won H; Iyer G; Canevari S; Colecchia M; Giannatempo P; Raggi D; Pierotti MA; De Braud FG; Solit DB; Rosenberg JE; Berger MF; Necchi A
    Clin Genitourin Cancer; 2016 Feb; 14(1):e81-90. PubMed ID: 26371421
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.
    Sleijfer S; Gorlia T; Lamers C; Burger H; Blay JY; Le Cesne A; Scurr M; Collin F; Pandite L; Marreaud S; Hohenberger P
    Br J Cancer; 2012 Aug; 107(4):639-45. PubMed ID: 22805326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial.
    Necchi A; Lo Vullo S; Giannatempo P; Raggi D; Calareso G; Togliardi E; Crippa F; Pennati M; Zaffaroni N; Perrone F; Busico A; Colecchia M; Nicolai N; Mariani L; Salvioni R
    Ann Oncol; 2017 Jun; 28(6):1346-1351. PubMed ID: 28383677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.
    Palma N; Morris JC; Ali SM; Ross JS; Pal SK
    Eur Urol; 2015 Jul; 68(1):168-70. PubMed ID: 25766722
    [No Abstract]   [Full Text] [Related]  

  • 17. Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
    Koinis F; Agelaki S; Karavassilis V; Kentepozidis N; Samantas E; Peroukidis S; Katsaounis P; Hartabilas E; Varthalitis II; Messaritakis I; Fountzilas G; Georgoulias V; Kotsakis A
    Br J Cancer; 2017 Jun; 117(1):8-14. PubMed ID: 28510571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy.
    Gerullis H; Eimer C; Ecke TH; Georgas E; Arndt C; Otto T
    Anticancer Drugs; 2013 Apr; 24(4):422-5. PubMed ID: 23407060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
    Yuen KC; Liu LF; Gupta V; Madireddi S; Keerthivasan S; Li C; Rishipathak D; Williams P; Kadel EE; Koeppen H; Chen YJ; Modrusan Z; Grogan JL; Banchereau R; Leng N; Thastrom A; Shen X; Hashimoto K; Tayama D; van der Heijden MS; Rosenberg JE; McDermott DF; Powles T; Hegde PS; Huseni MA; Mariathasan S
    Nat Med; 2020 May; 26(5):693-698. PubMed ID: 32405063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.
    Duffaud F; Sleijfer S; Litière S; Ray-Coquard I; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla SP; Dewji R; Marreaud S; Verweij J; van der Graaf WT
    Eur J Cancer; 2015 Nov; 51(17):2615-23. PubMed ID: 26321011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.